SFM
VRTX icon

Signet Financial Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Signet Financial Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,163
Closed -$3.8M – 280
2024
Q3 		$3.8M Buy
8,163
+51
+0.6% +$24.5K 0.48% 65
2024
Q2 		$3.8M Buy
8,112
+82
+1% +$35.6K 0.51% 61
2024
Q1 		$3.36M Buy
8,030
+122
+2% +$51.6K 0.46% 70
2023
Q4 		$3.22M Sell
7,908
-26
-0.3% -$9.61K 0.48% 68
2023
Q3 		$2.76M Sell
7,934
-96
-1% -$33.6K 0.46% 74
2023
Q2 		$2.83M Buy
8,030
+37
+0.5% +$12.5K 0.45% 73
2023
Q1 		$2.52M Buy
7,993
+68
+0.9% +$20.4K 0.42% 78
2022
Q4 		$2.29M Buy
7,925
+106
+1% +$32.3K 0.41% 83
2022
Q3 		$2.26M Buy
7,819
+184
+2% +$52.9K 0.44% 68
2022
Q2 		$2.15M Buy
+7,635
New +$2.04M 0.41% 70
2022
Q1 		– Sell
-201
Closed -$44K – 1319
2021
Q4 		$44K Buy
+201
New +$39.1K 0.01% 529
2018
Q4 		– Sell
-903
Closed -$174K – 820
2018
Q3 		$174K Buy
903
+59
+7% +$10.5K 0.03% 238
2018
Q2 		$144K Hold
844
– – 0.03% 261
2018
Q1 		$138K Buy
+844
New +$138K 0.02% 245

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Signet Financial Management's VRTX Position: Q4 2024 in Review

Signet Financial Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 8,163 shares — an estimated $3.8M sold.

Signet Financial Management first reported a position in VRTX in Q1 2018 and held it in 14 quarters. The position peaked at $3.8M in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Signet Financial Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Signet Financial Management sold 8,163 Vertex Pharmaceuticals shares in Q4 2024, an estimated $3.8M.
  • Signet Financial Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 14 quarters.
  • Signet Financial Management's Vertex Pharmaceuticals position peaked at $3.8M in Q2 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Signet Financial Management's 13F filing for Q4 2024, filed 13 Jan 2025.